On-demand recording of expert faculty presentations and case discussions on new clinical findings and regulatory approvals of PARP inhibitors in combination to treat patients with prostate cancer.
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/parpi-in-prostate-cancer-1/18642-27281
- Start Date: 2024-02-07 06:00:00
- End Date: 2024-02-07 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 68500.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 25000.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 68500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest